An out and out rebuttal would be an egotistical move and not in the shareholder interests as "maybe" will put a floor under the price. Managment and the Board are supposed to be aligned with shareholders, so should be their job to get a price that is reflect of FUTURE value, although self-preservation is a factor. The Invitation to Treat (not Offer in the true sense) is no where near reflecting the upside of this operation at the movement with grade and recovering both shaking-out, therefore and agree with East West. This opportunistic bid was precipitated by the price plunge recently owing to the revised down guidance and retail loosing their collective minds. With the US 10 year T-bill retracing, a 45 cps target by year end remains achievable, T/O bid or not. Let's see how short-term some holders are in this fickle market?.
- Forums
- ASX - By Stock
- TIE
- Ann: Response to Zhaojin Takeover Offer
Ann: Response to Zhaojin Takeover Offer, page-25
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TIE (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online